Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Dombernowsky

Showing results (71-80 of 211) with videos related to

Pageof 22
Sort By:
European Journal of Cancer & Clinical Oncology|January 1, 1982
Phase II trial of amsacrine (m-AMSA) in advanced ovarian carcinomaP Dombernowsky, P Siegenthaler, R Somers, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
Phase II study of teniposide in adenocarcinoma of the lungJ B Sørensen, F Bach, P Dombernowsky, et al.
Clinical Chemistry|October 1, 1993
Interpretation of results for tumor markers on the basis of analytical imprecision and biological variationG Sölétormos, V Schiøler, D Nielsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2001
Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapyT Sigsgaard, J Herrstedt, J Handberg, et al.
Clinical Chemistry and Laboratory Medicine|August 17, 2001
Interpretation of sequential measurements of cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), and tissue polypeptide antigen (TPA) based on analytical imprecision and biological variation in the monitoring of ovarian cancerM K Tuxen, G Sölétormos, P H Petersen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2001
Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapyM Ryberg, D Nielsen, K Osterlind, et al.
European Journal of Cancer (Oxford, England : 1990)|February 14, 2004
Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPAG Sölétormos, D Nielsen, V Schiøler, et al.
Cancer Treatment Reports|July 1, 1976
PHASE I clinical trial of an oral solution of VP-16-213N I Nissen, P Dombernowsky, H H Hansen, et al.
Ugeskrift for Laeger|January 1, 1996
[Male breast cancer. A review]S W Langer, M Krasnik, F R Hirsch, et al.
Cancer|July 15, 1980
Phase II trial of prednimustine, L-1031, (NSC-134087) in advanced breast cancerH T Mouridsen, D Kristensen, J H Nielsen, et al.
Pageof 22

Showing results (71-80 of 211) with videos related to

Sort By:
Pageof 22
European Journal of Cancer & Clinical Oncology|January 1, 1982
Phase II trial of amsacrine (m-AMSA) in advanced ovarian carcinomaP Dombernowsky, P Siegenthaler, R Somers, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
Phase II study of teniposide in adenocarcinoma of the lungJ B Sørensen, F Bach, P Dombernowsky, et al.
Clinical Chemistry|October 1, 1993
Interpretation of results for tumor markers on the basis of analytical imprecision and biological variationG Sölétormos, V Schiøler, D Nielsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2001
Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapyT Sigsgaard, J Herrstedt, J Handberg, et al.
Clinical Chemistry and Laboratory Medicine|August 17, 2001
Interpretation of sequential measurements of cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), and tissue polypeptide antigen (TPA) based on analytical imprecision and biological variation in the monitoring of ovarian cancerM K Tuxen, G Sölétormos, P H Petersen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 16, 2001
Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapyM Ryberg, D Nielsen, K Osterlind, et al.
European Journal of Cancer (Oxford, England : 1990)|February 14, 2004
Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPAG Sölétormos, D Nielsen, V Schiøler, et al.
Cancer Treatment Reports|July 1, 1976
PHASE I clinical trial of an oral solution of VP-16-213N I Nissen, P Dombernowsky, H H Hansen, et al.
Ugeskrift for Laeger|January 1, 1996
[Male breast cancer. A review]S W Langer, M Krasnik, F R Hirsch, et al.
Cancer|July 15, 1980
Phase II trial of prednimustine, L-1031, (NSC-134087) in advanced breast cancerH T Mouridsen, D Kristensen, J H Nielsen, et al.
Pageof 22